COX-2 inhibitors, including aspirin, celecoxib, and other NSAIDs, seem to be effective in colorectal cancer prevention [38], suggesting a pathogenic role of COX-2 in the development of CRC [27]. This evidence concerns the gene PTGS2 and colorectal cancer.